1.65
+0.08(+5.10%)
Currency In USD
| Previous Close | 1.57 |
| Open | 1.62 |
| Day High | 1.69 |
| Day Low | 1.6 |
| 52-Week High | 5 |
| 52-Week Low | 1.37 |
| Volume | 609,401 |
| Average Volume | 52,503 |
| Market Cap | 9.61M |
| PE | -0.72 |
| EPS | -2.3 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 2.11 |
| Change | 0.08 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $4.02 as of October 20, 2025 at a share price of $1.65. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 5 years ago, it would be worth $3.36 as of October 20, 2025 at a share price of $1.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinationCompany is prioritizing its lead program, WEE1 kin
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities wh
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 12:30 PM GMT
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities wh